List of Excipients in Branded Drug SODIUM FLUORIDE

Generic Drugs Containing SODIUM FLUORIDE

Company	Ingredient	NDC	Excipient
THE FEINSTEIN INSTITUTES FOR MEDICAL RESEARCH	sodium fluoride f 18	13267-542	SODIUM CHLORIDE
Shertech Laboratories LLC	sodium fluoride f 18	16129-002	SODIUM CHLORIDE
SOFIE Co dba SOFIE	sodium fluoride f-18	49609-002	SODIUM CHLORIDE
Essential Isotopes LLC	sodium fluoride f-18	51760-002	SODIUM CHLORIDE
Precision Nuclear LLC	sodium fluoride f-18	52768-125	SODIUM CHLORIDE

What are the Most Frequently-Used Excipients in SODIUM FLUORIDE?

# Of NDCs	Excipient
8	SODIUM CHLORIDE

Sodium Fluoride Excipient Strategy and Commercial Opportunities

Last updated: August 7, 2026

Sodium fluoride is a low-cost, established small-molecule active used in toothpaste, mouthrinses, prescription tablets and drops, dental gels, varnishes, and professional fluoride treatments. Its active-ingredient patent risk is minimal, while commercial differentiation depends on excipient selection, dosage-form performance, pediatric usability, dental-office workflow, stability, packaging, and regulatory positioning.

The strongest opportunities are private-label and contract-manufactured oral-care products, pediatric fluoride supplements, high-fluoride prescription products, xerostomia-focused formulations, unit-dose professional products, and formulations that reduce staining, bitterness, precipitation, or dosing errors.

What is sodium fluoride used for in pharmaceutical products?

Sodium fluoride supplies fluoride ions that promote enamel remineralization and reduce dental-caries risk. Its main pharmaceutical and quasi-pharmaceutical applications are:

Product category	Typical sodium fluoride role	Primary commercial channel
Toothpaste	Anticaries active	Retail, dental, private label
Mouthrinse	Anticaries active	Retail and prescription
Oral drops and tablets	Systemic fluoride supplementation where indicated	Pediatric and prescription
Chewable tablets and lozenges	Local and, depending on product, systemic fluoride delivery	Prescription and dental
Dental gels and foams	High-concentration topical treatment	Dental offices and institutions
Varnishes	Professional topical fluoride treatment	Dental practices and public-health programs
Custom compounded products	Patient-specific fluoride delivery	Specialty pharmacies and dental practices

U.S. anticaries products containing sodium fluoride are regulated through established FDA pathways, including the OTC anticaries drug framework and approved prescription products. Product labeling, concentration, age restrictions, and directions determine the applicable regulatory route (U.S. Food and Drug Administration [FDA], 2023a; Electronic Code of Federal Regulations [e-CFR], 2024a).

What excipients are most important in sodium fluoride formulations?

Excipient strategy depends on the dosage form. The central technical objective is to keep fluoride chemically available, prevent precipitation, maintain acceptable taste, and control dose uniformity.

Liquid drops, solutions, and mouthrinses

Common excipient classes include:

Excipient function	Examples	Strategic purpose
Vehicle	Purified water	Dissolves sodium fluoride and supports low-viscosity delivery
Humectant	Glycerin, sorbitol, propylene glycol	Improves mouthfeel and limits drying
Sweetener	Sorbitol, xylitol, sucralose, sodium saccharin	Masks bitterness
Buffer	Phosphate, citrate, or other compatible systems	Controls pH
Flavor	Peppermint, spearmint, fruit flavors	Improves adherence
Thickener	Cellulose derivatives, xanthan gum	Supports dose retention and mouthfeel
Preservative	Product-specific antimicrobial system	Controls microbial growth in multidose liquids
Chelator	Carefully selected chelating agents	Controls trace-metal effects where justified
Colorant	Approved water-soluble colorants	Supports product identification

Sodium fluoride is water-soluble, but liquid formulations require control of pH, ionic strength, microbial quality, and packaging compatibility. Formulators should avoid unnecessary calcium-containing excipients because fluoride can react with calcium to form poorly soluble calcium fluoride under favorable conditions. Magnesium, aluminum, iron, and other multivalent cations also require compatibility assessment.

Chewable tablets and lozenges

Chewable sodium fluoride products typically use:

• Microcrystalline cellulose or compressible fillers
• Mannitol or sorbitol for cooling mouthfeel
• Povidone or another binder
• Crospovidone or croscarmellose sodium where disintegration is needed
• Magnesium stearate or an alternative lubricant
• Flavor and sweetener systems
• Film coating, when needed for handling or taste control

The primary development issue is dose uniformity at low active loading. A tablet containing a small fluoride dose can have a high excipient-to-active ratio. Content uniformity, blend segregation, lubricant distribution, and compression behavior therefore require tighter control than the low material cost would suggest.

Direct compression is commercially attractive because it reduces processing steps. Wet granulation may improve blend uniformity and tablet robustness but introduces moisture exposure and a larger process-validation burden.

Toothpaste and dental gels

Toothpaste excipients must preserve sodium fluoride availability while delivering acceptable rheology and cleaning performance. Typical classes include:

• Hydrated silica or other abrasive
• Humectants such as glycerin and sorbitol
• Water
• Cellulose gum, carrageenan, xanthan gum, or other rheology modifiers
• Surfactants such as sodium lauryl sulfate or milder alternatives
• Sweeteners
• Flavor oils
• Preservatives where required
• Opacifiers and colorants

Abrasive and surfactant selection has direct commercial relevance. Sodium fluoride is generally easier to formulate than stannous fluoride because stannous fluoride has greater compatibility and stability challenges. The formulation must still be tested for available fluoride over shelf life, especially when abrasive surfaces, metal ions, high water activity, or incompatible flavor components are present.

The FDA OTC anticaries framework identifies sodium fluoride as an established active ingredient for certain oral-care products. Concentration, dosage form, labeling, and claims must remain within the applicable monograph conditions or approved application (e-CFR, 2024a).

What formulation patents protect sodium fluoride products?

Sodium fluoride itself has limited modern composition-of-matter patent value. The molecule is an old inorganic salt with established pharmaceutical use. Commercial protection usually comes from formulation, delivery, packaging, process, or brand assets rather than from the active ingredient.

Potentially protectable features include:

Protection area	Examples
Taste masking	Multi-layer coatings, flavor systems, bitterness suppression
Fluoride stability	pH-controlled systems, low-metal excipient systems, oxygen or moisture controls
Dental delivery	Adhesive gels, prolonged-contact varnishes, bioadhesive films
Pediatric delivery	Unit-dose drops, dose-limiting dispensers, child-resistant systems
Stain control	Compatibility systems that reduce interactions with chromogenic ingredients
Controlled release	Mucoadhesive tablets, extended-contact lozenges
Manufacturing	Low-dose blending, granulation, filling, and content-uniformity processes
Packaging	Unit-dose sachets, metered dispensers, moisture-barrier systems

These rights may support a differentiated product, but they generally do not prevent competitors from selling standard sodium fluoride tablets, drops, toothpaste, or rinses using different excipients and processes.

How many patents cover sodium fluoride products?

There is no single meaningful patent count for sodium fluoride because the relevant rights are distributed across different products, jurisdictions, assignees, and expired patent families.

The practical assessment is:

1. Sodium fluoride has no meaningful surviving basic-compound patent barrier.
2. Standard dosage forms are vulnerable to generic and private-label competition.
3. Active rights may exist around specialized delivery systems, packaging, manufacturing, or combinations.
4. Patent relevance must be assessed by product claim scope, not by the presence of “sodium fluoride” in a patent document.
5. Patent expiration and enforceability vary by country.

A freedom-to-operate review should search sodium fluoride, fluoride ion delivery, anticaries formulations, dental varnishes, mucoadhesive systems, pediatric dispensers, and relevant assignees. It should also screen continuation, divisional, and national-phase filings.

When does sodium fluoride lose exclusivity?

Sodium fluoride has already lost exclusivity as an active pharmaceutical ingredient. The commercial question is product-specific.

Exclusivity type	Sodium fluoride position
Basic compound patent	Generally expired
Standard formulation patent	Usually expired or commercially weak
FDA regulatory exclusivity	Product-specific; not inherent to sodium fluoride
Orphan exclusivity	Not generally associated with routine sodium fluoride products
Pediatric exclusivity	Possible only if separately granted to a qualifying product
Trademark exclusivity	Brand-specific and renewable
Trade-secret protection	Possible for manufacturing, flavor, or process know-how

FDA-approved products can have listed patents or exclusivity periods even when the active ingredient is old. A sponsor must review the current FDA Orange Book for the specific reference product and dosage form before filing an abbreviated new drug application or launching a competing product (FDA, 2024a).

What is the Orange Book status of sodium fluoride?

The Orange Book is product-specific rather than ingredient-wide. It identifies approved drug products, therapeutic equivalence information, patents submitted for certain products, and applicable exclusivity data.

For sodium fluoride, the commercial expectation is:

• Standard products generally have high substitution risk.
• Patent listings, where present, are likely to relate to a particular formulation, delivery system, or product presentation.
• A generic applicant must assess whether a Paragraph IV certification is required for any listed patent.
• OTC toothpaste and many oral-care products may follow monograph pathways rather than an ANDA strategy.
• Prescription fluoride tablets, drops, or other approved products require product-specific regulatory analysis.

The FDA Orange Book database should be reviewed immediately before submission because listed patents, delistings, exclusivity, and therapeutic-equivalence determinations can change (FDA, 2024a).

What Paragraph IV challenges are possible for sodium fluoride?

A Paragraph IV challenge is relevant only when an ANDA references an approved product with an Orange Book-listed patent. Sodium fluoride’s old active ingredient does not itself create a Paragraph IV barrier.

Potential challenge targets include:

• A listed formulation patent
• A controlled-release dosage form
• A specialized dispensing system
• A method-of-use patent
• A combination product containing sodium fluoride and another active
• A professional dental product with a proprietary delivery system

For ordinary sodium fluoride tablets or drops, the principal commercial risk is usually rapid generic entry or therapeutic substitution rather than prolonged patent litigation.

What method-of-use patents protect sodium fluoride?

Method-of-use claims may cover:

• Prevention of dental caries in defined age groups
• Treatment of high-caries-risk populations
• Use in patients with xerostomia
• Use after dental procedures
• Use with orthodontic appliances
• Professional fluoride treatment protocols
• Specific dosing schedules or delivery methods

Method-of-use protection is narrower than composition protection. A competitor may avoid infringement by changing the label, dosage form, patient population, concentration, or administration schedule. Regulatory strategy must account for label carve-outs and induced-infringement risk.

What FDA regulatory pathways apply to sodium fluoride?

OTC oral-care products

Sodium fluoride toothpaste, rinse, gel, and related products may qualify under the FDA anticaries drug monograph if the product meets applicable active-ingredient concentrations, labeling, dosage form, and manufacturing requirements.

A monograph-compliant product can have a lower development and regulatory burden than a new NDA product. Commercial success depends more heavily on formulation quality, branding, distribution, flavor, packaging, and claims discipline.

Prescription products

Prescription tablets, drops, and other dosage forms may require an approved application or an ANDA referencing a suitable listed drug. Pediatric fluoride supplementation is particularly sensitive to dosing instructions, age, weight, dietary fluoride exposure, and the risk of accidental ingestion.

Professional dental products

Varnishes, gels, foams, and office-use products require product-specific classification and labeling analysis. The regulatory pathway depends on formulation, concentration, intended use, claims, route of administration, and whether the product is supplied for professional or consumer use.

Which companies are challenging sodium fluoride products?

Competition is fragmented across multinational consumer-health companies, generic pharmaceutical manufacturers, dental suppliers, private-label manufacturers, and contract development and manufacturing organizations.

Competitive groups include:

• Consumer-health companies selling toothpaste and mouthrinse
• Generic manufacturers supplying tablets and oral liquids
• Dental distributors supplying varnishes, gels, and foams
• Private-label retailers
• Specialty manufacturers producing pediatric and institutional products
• Compounding pharmacies serving customized prescriptions

Competitive intensity is highest for standard toothpaste, rinse, tablets, and drops. It is lower for products requiring specialized filling, unit-dose packaging, professional distribution, validated fluoride-release testing, or complex taste-masking systems.

What commercial opportunities exist for sodium fluoride excipients?

Pediatric fluoride products

Pediatric products offer the clearest excipient-led opportunity. Differentiation can come from:

• Precise metered dosing
• Low-volume administration
• Palatable fruit flavors
• Sugar-free formulations
• Alcohol-free liquids
• Child-resistant packaging
• Unit-dose delivery
• Reduced staining and residue
• Improved caregiver instructions

The commercial risk is dosing error. The product should use a dispenser that limits measurement variability and makes the intended dose obvious.

Xerostomia and high-risk dental populations

Patients with dry mouth, orthodontic appliances, root-surface caries, or elevated caries risk may support higher-value products. Potential dosage forms include high-fluoride toothpaste, adhesive gels, sustained-contact lozenges, and professional-use products.

Excipients can improve retention, lubrication, taste, and residence time. Claims must remain aligned with the product’s regulatory status.

Professional unit-dose products

Dental practices value products that reduce chair time, simplify infection control, and minimize waste. Commercially attractive designs include:

• Single-use varnish doses
• Metered gel dispensers
• Preloaded trays
• Tamper-evident packaging
• Low-mess formulations
• Products with clear fluoride-content labeling

Packaging and workflow improvements can create stronger differentiation than a small change in excipient composition.

Private-label and contract manufacturing

Sodium fluoride is well suited to private-label programs because the active ingredient is inexpensive, established, and available from multiple suppliers. Contract manufacturers can differentiate through:

• Flavor development
• Rapid scale-up
• Flexible batch sizes
• Low-dose tablet manufacturing
• Tube and sachet filling
• Stability-indicating fluoride assays
• Regulatory documentation
• Retailer-specific packaging

Margins are generally better in differentiated professional or pediatric formats than in commodity toothpaste or standard tablets.

What manufacturing and intellectual-property barriers exist?

The active ingredient creates few manufacturing barriers. The relevant barriers are operational:

• Low-dose content uniformity
• Control of trace metals
• Prevention of fluoride precipitation
• Microbial control in aqueous products
• Flavor and preservative compatibility
• Packaging moisture protection
• Accurate dispensing
• Stability testing for available fluoride
• Scale-up of rheology and filling performance
• Validation of cleaning and cross-contamination controls

Manufacturers should qualify sodium fluoride for assay, identity, particle characteristics, heavy metals, water content, and microbial quality as appropriate to the dosage form. Supplier changes can affect taste, dissolution, tablet compression, and trace-ion profiles even when the active assay remains compliant.

How strong is the sodium fluoride patent estate?

The patent estate is weak for standard products and potentially stronger for specialized delivery systems.

Product concept	Patent strength	Generic or private-label risk
Standard sodium fluoride tablet	Low	High
Standard oral drops	Low	High
Conventional toothpaste	Low to moderate	High
High-fluoride specialty toothpaste	Moderate	Moderate to high
Mucoadhesive fluoride delivery	Moderate to strong	Moderate
Proprietary varnish system	Moderate	Moderate
Metered pediatric dispenser	Moderate	Moderate
Novel combination product	Product-specific	Product-specific
Manufacturing process	Narrow to moderate	Design-around likely

Trade dress, trademarks, flavor identity, packaging, customer contracts, and regulatory execution may provide more durable commercial value than composition patents.

What generic launch scenarios exist for sodium fluoride?

Immediate commodity entry

A manufacturer launches a standard tablet, liquid, toothpaste, or rinse using established excipients and low-cost packaging. This strategy requires efficient procurement and distribution.

Therapeutically equivalent prescription entry

An ANDA applicant references an approved prescription product and competes through price, wholesaler access, and formulary placement. Patent and exclusivity review is product-specific.

Monograph-based OTC launch

A company develops a compliant toothpaste, rinse, gel, or related product without relying on novel intellectual property. Brand, flavor, packaging, and retailer placement become the main competitive levers.

Differentiated specialty launch

A sponsor uses a protected or technically differentiated formulation, such as a sustained-contact gel, pediatric metered liquid, or professional unit-dose varnish. This model supports higher pricing but requires stronger clinical, stability, packaging, and regulatory documentation.

How does sodium fluoride compare with competing fluoride actives?

Active	Main strengths	Main formulation issues	Competitive position
Sodium fluoride	Low cost, high familiarity, broad regulatory history	Taste, metal-ion compatibility, low-dose uniformity	Strong commodity and private-label position
Stannous fluoride	Anticaries and broader oral-care positioning in some products	Greater stability, staining, and compatibility concerns	Differentiated consumer and professional products
Sodium monofluorophosphate	Established toothpaste active	Assay and compatibility considerations	Strong toothpaste presence
Amine fluoride	Film-forming and specialty positioning in some markets	Regional regulatory and supply considerations	Niche or premium positioning

Sodium fluoride is usually the simplest active from a formulation and sourcing perspective. It is less defensible on intellectual property than products built around novel delivery, combination claims, or proprietary clinical positioning.

What revenue exposure does sodium fluoride create?

Revenue exposure is highest for products with:

• Broad retail distribution
• Large pediatric or household user bases
• Reimbursement or formulary dependence
• Dental-office repeat purchasing
• Private-label retailer contracts
• High-volume toothpaste or rinse production

The principal downside is price erosion. Standard sodium fluoride products can lose share rapidly when multiple suppliers enter. A portfolio should separate commodity products from differentiated formats and avoid relying on one high-volume SKU.

A practical commercial model should measure:

1. Active and excipient cost per dose
2. Packaging cost per unit
3. Manufacturing yield and batch size
4. Stability failure rate
5. Retailer or dental-distributor margin
6. Expected generic price erosion
7. Regulatory maintenance cost
8. Switching cost for dental professionals and caregivers
9. Patent and trade-secret durability
10. Geographic registration requirements

What geographic markets offer sodium fluoride opportunities?

Sodium fluoride has broad global relevance because dental caries remains a major oral-health burden and fluoride products are established in many markets. Regulatory treatment differs by country.

Key geographic variables include:

• Whether toothpaste is regulated as a cosmetic, medicine, or hybrid product
• Permitted fluoride concentration
• Child-use labeling
• Requirements for fluoride availability testing
• Restrictions on claims
• Local language and warning requirements
• Import controls for pharmaceutical ingredients
• Public-health procurement standards
• Dental reimbursement and professional-use rules

The United States and European markets offer mature competition and strong regulatory infrastructure. Emerging markets may offer higher volume growth but require local registration, supply-chain qualification, and price-sensitive product design. Public-health tenders can favor stable, low-cost products with simple packaging and validated shelf life.

Key Takeaways

• Sodium fluoride has minimal basic patent risk and high competition in standard dosage forms.
• Excipient strategy is the main route to differentiation.
• The most important technical issues are fluoride availability, precipitation control, taste, microbial stability, dose uniformity, and packaging.
• Pediatric metered liquids, high-fluoride specialty products, xerostomia products, professional unit-dose systems, and private-label programs offer the strongest commercial opportunities.
• OTC anticaries monograph compliance can reduce regulatory complexity for qualifying oral-care products.
• Prescription products require product-specific Orange Book, exclusivity, and Paragraph IV analysis.
• Biosimilar risk is not relevant because sodium fluoride is a small inorganic-molecule active, not a biologic.
• Manufacturing and packaging know-how may provide more practical value than patents.
• Commodity products face rapid price erosion; specialized delivery and professional workflow products have better margin potential.

FAQs About Sodium Fluoride Excipient and Patent Strategy

Can sodium fluoride be formulated with calcium carbonate?

Calcium-containing excipients require compatibility testing because fluoride can form poorly soluble calcium fluoride. The formulation should demonstrate acceptable available fluoride and stability throughout shelf life.

Is sodium fluoride suitable for sugar-free pediatric products?

Yes. Sorbitol, xylitol, mannitol, sucralose, and other sweetener systems can support sugar-free products, subject to tolerability, taste, labeling, and age-appropriate use requirements.

Does sodium fluoride require a biosimilar development program?

No. Sodium fluoride is a small inorganic-molecule drug substance. The relevant pathways are generic, OTC monograph, or product-specific approval pathways, not biosimilar regulation.

Can a sodium fluoride product receive new patent protection?

A new patent may protect a novel formulation, delivery system, manufacturing method, packaging system, or combination. It generally cannot restore exclusivity to the established sodium fluoride molecule itself.

What is the largest commercial risk for a sodium fluoride launch?

For standard products, the largest risk is rapid price and share erosion from generic, private-label, and established consumer-health competitors. Differentiated products face greater development and regulatory costs but can reduce direct commodity competition.

References

Electronic Code of Federal Regulations. (2024a). 21 C.F.R. Part 355: Anticaries drug products for over-the-counter human use. https://www.ecfr.gov/

U.S. Food and Drug Administration. (2023a). Anticaries drug products for over-the-counter human use: Final monograph and related regulatory requirements. https://www.fda.gov/

U.S. Food and Drug Administration. (2024a). Approved drug products with therapeutic equivalence evaluations: Orange Book. https://www.accessdata.fda.gov/scripts/cder/ob/

U.S. Pharmacopeia. (2024). Sodium fluoride monograph. In United States Pharmacopeia and National Formulary. United States Pharmacopeial Convention.

National Library of Medicine. (2024). DailyMed: Sodium fluoride drug labels. https://dailymed.nlm.nih.gov/